Boehringer Ingelheim’s Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn’t cure IPF but clinical trial results showed it slowed disease progression.
The post Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF appeared first on MedCity News.
